Protamine-Based Nanotherapeutics for Gene Delivery to Glioblastoma Cells
Molecular Pharmaceutics · 2025
DOI: 10.1021/acs.molpharmaceut.4c01269 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Sheila Barrios-Esteban und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), University of Santiago de Compostela, Campus Vida, 15706 Santiago de Composte…. Hauptthemen laut MEDLINE: Protamines, Glioblastoma, Nanoparticles, Gene Transfer Techniques. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agencia Estatal de Investigaci?n, Xunta de Galicia, Conseller?a de Cultura, Educaci?n e Ordenaci?n Universitaria, Xunta de Galicia.
Abstract (Originalsprache)
Isocitrate dehydrogenase wild-type glioblastoma is the most aggressive primary brain tumor classified as grade 4 of malignancy. Standard treatment, combining surgical resection, radiotherapy, and chemotherapy, often leads to severe side effects, with the emergence of tumor recurrence in all cases. Nucleic acid-based therapy has emerged as a promising strategy for cancer treatment. Non-viral nanosystems have become the vehicles of choice for gene delivery, due to their efficient nucleic acid encapsulation, protection, and intracellular transport. This work explores the potential of a formulation of low molecular weight protamine (LMWP) and dextran sulfate for gene delivery. The nanoparticles (NPs) were evaluated in terms of particle size, surface charge, morphology, and capacity to condense different nucleic acids. NPs formed by ionic complexation resulted in a homogeneous population of spherical particles with a low polydispersity index (PDI), small size, and positive surface charge. Competitive displacement assay demonstrated that the NPs could condense nucleic acids without alterations in their morphology and physicochemical characteristics, even after long-term storage. The efficacy of this formulation as a gene delivery system was evaluated in vitro in different glioblastoma cell lines and three-dimensional (3D) spheroids and in vivo using zebrafish models, showing negligible toxicity, efficient internalization, and consistent expression of fluorescent/luminescent proteins. Overall, these cationic polymeric NPs show promising features for their use as non-viral gene delivery vehicles for glioblastoma treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), University of Santiago de Compostela, Campus Vida, 15706 Santiago de Compostela, Spain.
- School of Veterinary, University of Santiago de Compostela, Campus de Lugo, 27002 Lugo, Spain.
- Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain.
- Children's Brain Tumor Research Centre (CBTR) and Biodiscovery Institute (BDI), University of Nottingham, University Park, NG7 2RD Nottingham, U.K.
- School of Pharmacy, bBoots Science Building (BSB), University of Nottingham, East Dr, NG7 2TQ Nottingham, U.K.
- Department Pharmacology, Pharmacy and Pharmaceutical Technology, School of Pharmacy, University of Santiago de Compostela, Campus Vida, 15706 Santiago de Compostela, Spain.
ORCID-Profile: María de la Fuente, Ruman Rahman, Cameron Alexander, Marcos Garcia-Fuentes, Noemi S Csaba
Förderung
- Agencia Estatal de Investigaci?n
- Xunta de Galicia
- Conseller?a de Cultura, Educaci?n e Ordenaci?n Universitaria, Xunta de Galicia
- British Spanish Society
- Diputaci?n Provincial de La Coru?a
Zitieren
APA
Barrios-Esteban, S., Reimóndez-Troitiño, S., Cabezas-Sainz, P., de la Fuente, M., Sánchez, L., Rahman, R., Alexander, C., Garcia-Fuentes, M., & Csaba, N. S. (2025). Protamine-Based Nanotherapeutics for Gene Delivery to Glioblastoma Cells. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c01269
Vancouver
Barrios-Esteban S, Reimóndez-Troitiño S, Cabezas-Sainz P, de la Fuente M, Sánchez L, Rahman R, et al. Protamine-Based Nanotherapeutics for Gene Delivery to Glioblastoma Cells. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.4c01269
BibTeX
@article{BarriosEsteban2025,
author = {Barrios-Esteban, Sheila and Reimóndez-Troitiño, Sonia and Cabezas-Sainz, Pablo and de la Fuente, María and Sánchez, Laura and Rahman, Ruman and Alexander, Cameron and Garcia-Fuentes, Marcos and Csaba, Noemi S},
title = {Protamine-Based Nanotherapeutics for Gene Delivery to Glioblastoma Cells},
journal = {Molecular Pharmaceutics},
year = {2025},
doi = {10.1021/acs.molpharmaceut.4c01269}
}
EUVIMED